Session A: Anti-Cancer for Today and Tomorrow: Directions, Strategies and Collaborations
Session B: Case Studies: Replenishing the Oncology Pipelines
Session C: New Prospects and Platforms for Targeted Cancer Therapy
Session D: Biomarker and Translational Research in Clinical Oncology
Learning how the industry and academia partnering in the anti-cancer drug R&D
How the early success of anti-cancer drug and other targeted therapies has shaped Big Pharma approaches to personalized medicine
What are the main concerns for market access to targeted therapies for cancer
Opportunity for biotech: what kind of opportunities are they looking to bring in
What has been learned thus far with regard to co-development of therapy and diagnostic
Nanomagnetic particle for cancer diagnostic and treatment
Early clinical trials case study
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
